St. Anna Children's Hospital, Pediatric Clinic, Medical University, Vienna, Austria.
Labdia Labordiagnostik, Vienna, Austria.
Leukemia. 2022 Dec;36(12):2769-2783. doi: 10.1038/s41375-022-01720-z. Epub 2022 Oct 20.
Hyperdiploidy is the largest genetic entity B-cell precursor acute lymphoblastic leukemia in children. The diagnostic hallmark of its two variants that will be discussed in detail herein is a chromosome count between 52 and 67, respectively. The classical HD form consists of heterozygous di-, tri-, and tetrasomies, whereas the nonclassical one (usually viewed as "duplicated hyperhaploid") contains only disomies and tetrasomies. Despite their apparently different clinical behavior, we show that these two sub-forms can in principle be produced by the same chromosomal maldistribution mechanism. Moreover, their respective array, gene expression, and mutation patterns also indicate that they are biologically more similar than hitherto appreciated. Even though in-depth analyses of the genomic intricacies of classical HD leukemias are indispensable for the elucidation of the disease process, the ensuing results play at present surprisingly little role in treatment stratification, a fact that can be attributed to the overall good prognoses and low relapse rates of the concerned patients and, consequently, their excellent treatment outcome. Irrespective of this underutilization, however, the detailed genetic characterization of HD leukemias may, especially in planned treatment reduction trials, eventually become important for further treatment stratification, patient management, and the clinical elucidation of outcome data. It should therefore become an integral part of all upcoming treatment studies.
超二倍体是儿童 B 细胞前体急性淋巴细胞白血病中最大的遗传实体。本文将详细讨论的其两个变体的诊断标志是染色体计数分别为 52 和 67。经典 HD 形式由杂合的二、三、四倍体组成,而非经典的形式(通常被视为“重复超二倍体”)仅包含二倍体和四倍体。尽管它们的临床行为显然不同,但我们表明,这两种亚型原则上可以通过相同的染色体分布不均机制产生。此外,它们各自的阵列、基因表达和突变模式也表明它们在生物学上比以前认识的更为相似。尽管深入分析经典 HD 白血病的基因组复杂性对于阐明疾病过程是必不可少的,但目前这些结果在治疗分层中的作用令人惊讶地小,这一事实可以归因于相关患者的总体良好预后和低复发率,以及因此而获得的极佳治疗效果。然而,无论这种未充分利用的情况如何,HD 白血病的详细遗传特征,特别是在计划的治疗减少试验中,最终可能对进一步的治疗分层、患者管理以及对结果数据的临床阐明变得重要。因此,它应该成为所有即将进行的治疗研究的一个组成部分。